- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05117242
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination Pembrolizumab Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial is a randomized, open-label trial evaluating the safety and efficacy of acasunlimab (GEN1046) as monotherapy and in combination therapy with pembrolizumab.
The trial consists of two parts; a safety phase and an extension phase. The extension phase will be initiated once the safety phase is completed.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Genmab A/S Trial Information
- Phone Number: +45 70202728
- Email: clinicaltrials@genmab.com
Study Locations
-
-
-
Bordeaux, France
- Recruiting
- Institut Bergonié
-
Brest, France
- Recruiting
- Hopital Morvan CHU de Brest
-
Rouen, France
- Recruiting
- Hopital Charles Nicolle Chu Rouen
-
St Mande, France
- Recruiting
- Hopital dInstruction Des Armees Begin
-
Strasbourg, France
- Recruiting
- Institut de cancérologie Strasbourg Europe (ICANS)
-
Suresnes, France
- Recruiting
- Hopital FOCH
-
Villejuif, France
- Recruiting
- Gustave Roussy
-
-
-
-
-
Frankfurt am main, Germany
- Recruiting
- IKF Krankenhaus Nordwest
-
Hanover, Germany
- Recruiting
- Med.Hochschule Hannover Klinik für Pneumologie
-
Hessen, Germany
- Recruiting
- Universitatsklinik Giessen und Marburg Standort Giessen
-
Immenhausen, Germany
- Recruiting
- LKI Lungenfachklinik Immenhausen
-
Regensburg, Germany
- Recruiting
- Department of Internal Medicine II
-
-
-
-
-
Catania, Italy
- Recruiting
- Azienda Ospedaliera Universitaria Policlinico G Rodolico San Marco
-
Genova, Italy
- Recruiting
- ASL 3 Genovese Ospedale Villa Scassi
-
Milano, Italy
- Recruiting
- Irccs Istituto Europeo Di Oncologia
-
Napoli, Italy
- Recruiting
- UOC Oncoematologia AOU L.Vanvitelli
-
Palermo, Italy
- Recruiting
- La Maddalena SPA
-
Ravenna, Italy
- Recruiting
- AUSL della Romagna
-
Roma, Italy
- Recruiting
- Ifo Regina Elena
-
-
-
-
-
Amsterdam, Netherlands
- Recruiting
- VU University Medical Center
-
Amsterdam, Netherlands
- Recruiting
- Netherlands Cancer Institute
-
Leiden, Netherlands
- Recruiting
- Leids Universitair Medisch Centrum
-
Rotterdam, Netherlands
- Recruiting
- Erasmus MC
-
-
-
-
-
Olsztyn, Poland
- Recruiting
- Samodzielny Publiczny Zespol Gruzlicy I Chorob Pluc
-
Poznań, Poland
- Recruiting
- Med Polonia Sp. z o.o.
-
Prabuty, Poland
- Recruiting
- Szpital Specjalistyczny w Prabutach Sp. z o.o.
-
Warszawa, Poland
- Recruiting
- Maria Sklodowska-Curie National Research Institute of Oncology
-
-
-
-
-
Braga, Portugal
- Recruiting
- Clinical Academic Center Braga
-
Lisbon, Portugal
- Recruiting
- Centro Clinico Champalimaud
-
Lisbon, Portugal
- Recruiting
- Instituto Portugues de Oncologio de Lisboa
-
Porto, Portugal
- Recruiting
- Centro Hospitalar Universitário do Porto - Hospital de Santo Antonio
-
-
-
-
-
Barcelona, Spain
- Recruiting
- Hospital Universitari Vall dHebron
-
Madrid, Spain
- Recruiting
- Hospital Universitario 12 de Octubre
-
Madrid, Spain
- Recruiting
- Hospital Universitario Fundacion Jimenez Diaz
-
Madrid, Spain
- Recruiting
- MD Anderson Cancer Center
-
Madrid, Spain
- Recruiting
- Clínica Universidad de Navarra CUN
-
Málaga, Spain
- Recruiting
- Hospital Universitario Virgen de la Victoria
-
Pamplona, Spain
- Recruiting
- Clinica Universidad de Navarra
-
Valencia, Spain
- Recruiting
- Hospital Clinico Universitario de Valencia
-
Valencia, Spain
- Recruiting
- Fundación Instituto Valenciano de Oncología
-
-
-
-
-
Cheltenham, United Kingdom
- Recruiting
- Cheltenham General Hospital
-
London, United Kingdom
- Recruiting
- University College London
-
London, United Kingdom
- Recruiting
- King's College London, Guy's Hospital
-
Manchester, United Kingdom
- Recruiting
- The Christie Hospital
-
-
-
-
California
-
Santa Rosa, California, United States, 95403
- Recruiting
- St. Joseph Heritage Healthcare
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Recruiting
- Florida Cancer Specialists - FCS South
-
Saint Petersburg, Florida, United States, 33705
- Recruiting
- Florida Cancer Center
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Cancer Institute
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Cancer & Hematology Centers of Western Michigan CHCWM P.C.
-
Southfield, Michigan, United States, 48075
- Recruiting
- Oncology Clinical Trials Ascension Providence Hospital
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Recruiting
- Penn State Cancer Institute Penn State Health Herhsey Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Have signed an informed consent form (ICF)
- Be at least 18 years of age.
- Have histologically or cytologically confirmed diagnosis of stage 4 NSCLC with at least 1 prior line of systemic therapy containing an anti-PD-1/PD-L1 mAb for metastatic disease
- Have a tumor PD-L1 expression result available prior to first treatment demonstrating PD-L1 expression in ≥1% of tumor cells as assessed by a central or local laboratory during screening.
- Have measurable disease per RECIST v1.1.
- Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1.
- Have life expectancy of at least 3 months.
- Have adequate organ and bone marrow function as defined in the protocol.
Key Exclusion Criteria:
- Documentation of known EGFR, KRAS, RET, ROS1, BRAF mutations, NTRK gene infusions, RET arrangement, ALK gene rearrangements, high-level MET amplification, or METex 14 skipping. Note: Subjects harboring such mutations, gene rearrangements or amplifications may be enrolled in the trial, if subjects have received prior approved targeted therapy for such mutations, the subject may still be eligible for this trial.
- Treatment with an anti-cancer agent within 28 days prior to acasunlimab administration.
- Any investigational agent for the treatment of stage 4 NSCLC.
- Radiotherapy within 14 days prior to first dose of acasunlimab. Note: palliative radiotherapy will be allowed for local pain control under certain conditions.
- Chronic systemic immunosuppressive corticosteroid doses, ie, prednisone >10 mg daily or a cumulative dose >150 mg prednisone within 14 days before the first acasunlimab administration.
- Subject has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
- Subject has contraindications to the use of pembrolizumab per local prescribing information.
- Subject has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis (interstitial lung disease).
- Ongoing or active infection requiring intravenous treatment with anti-infective therapy or any ongoing systemic inflammatory condition requiring further diagnostic work-up or management during screening.
- Symptomatic congestive heart failure (grade III or IV as classified by the New York Heart Association), unstable angina pectoris, or cardiac arrhythmia.
- Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, despite optimal medical management.
- Ongoing or recent (within 6 months) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for irAEs.
Subject has a known history of any of the following:
- Grade 3 or higher irAEs that led to treatment discontinuation of a prior immunotherapy treatment.
- Myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade.
- Liver disease (eg, alcoholic hepatitis or non-alcoholic steatohepatitis, drug-related or autoimmune hepatitis, or evidence of hepatic cirrhosis).
- Organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of acasunlimab.
- Grade 3 or higher allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
Treatment with acasunlimab once every 21 days for the first 2 cycles and then every 42 days in subsequent cycles
|
Acasunlimab will be administered intravenously (IV)
Other Names:
|
Experimental: Arm B
Treatment with acasunlimab + pembrolizumab once every 21 days
|
Acasunlimab will be administered intravenously (IV)
Other Names:
Pembrolizumab will be administered IV
Other Names:
|
Experimental: Arm C
Treatment with acasunlimab+ pembrolizumab once every 42 days
|
Acasunlimab will be administered intravenously (IV)
Other Names:
Pembrolizumab will be administered IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: From first treatment to approximately 27 weeks after last subject's first dose
|
ORR will be measured as the proportion of subjects with a confirmed response of complete response (CR) or partial response (PR) as per RECIST v1.1
|
From first treatment to approximately 27 weeks after last subject's first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DOR)
Time Frame: From onset date of response until disease progression/death/lost to follow-up/start of new anticancer therapy or withdrawal of consent, whichever occurs first (an expected average of 6 months)
|
DOR will be measured as the time from initial onset of CR or PR to first radiographic progression as per RECIST v. 1.1 or death from any cause, whichever occurs first.
|
From onset date of response until disease progression/death/lost to follow-up/start of new anticancer therapy or withdrawal of consent, whichever occurs first (an expected average of 6 months)
|
Time to response (TTR)
Time Frame: From first treatment to date of onset of initial response (CR or PR) as per RECIST v.1.1 (an expected average of 6 months)
|
TTR will be measured as the time from first treatment to onset of initial response (CR or PR) as per RECIST v.1.1
|
From first treatment to date of onset of initial response (CR or PR) as per RECIST v.1.1 (an expected average of 6 months)
|
Progression-free survival (PFS)
Time Frame: From first treatment to first documented progression or death due to any cause (an expected average of 6 months)
|
PFS will be measured from date of first treatment until date of radiographic progression as per RECIST v.1.1 or until death from any cause, whichever occurs first
|
From first treatment to first documented progression or death due to any cause (an expected average of 6 months)
|
Overall survival (OS)
Time Frame: From first treatment to date of death (assessed up to 3 years after the last participant's first dose in the trial)
|
Defined as time to death from of any cause
|
From first treatment to date of death (assessed up to 3 years after the last participant's first dose in the trial)
|
Incidence and severity of adverse events (AEs) and laboratory abnormalities
Time Frame: Throughout the trial until end of safety follow-up period (60 days or 90 days after last dose)
|
Incidence of treatment-emergent AEs as assessed by CTCAE v5.0.
Laboratory parameters graded by CTCAE v5.0
|
Throughout the trial until end of safety follow-up period (60 days or 90 days after last dose)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- GCT1046-04
- 2021-001928-17 (EudraCT Number)
- 1004314 (Other Identifier: IRAS ID; UK Research Summaries Database)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer Metastatic
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
ElephasBeaufort CRORecruitingNSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Western Regional Medical CenterTerminatedNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung CancerUnited States
-
Genentech, Inc.CompletedNon-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, MelanomaUnited States
-
Incyte CorporationZai Lab (Shanghai) Co., Ltd.Active, not recruitingMetastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung CancerChina, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
-
Shandong Boan Biotechnology Co., LtdCompletedMetastatic Colorectal Cancer | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer RecurrentChina
-
TheRas, IncRecruitingNSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12CUnited States
-
Tesaro, Inc.Active, not recruitingNeoplasms | Solid Tumor | Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer MetastaticUnited States
-
University Hospital Southampton NHS Foundation...Royal Bournemouth and Christchurch Hospitals NHS Foundation TrustUnknownNon Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer MetastaticUnited Kingdom
Clinical Trials on Acasunlimab
-
GenmabBioNTech SEActive, not recruitingCervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial CarcinomaUnited States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine
-
GenmabBioNTech SENot yet recruitingAdvanced Endometrial CancerKorea, Republic of, Spain, Belgium, United States, Denmark, Italy
-
GenmabBioNTech SEActive, not recruiting